Overview

Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus

Status:
Terminated
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of secukinumab on the preservation of pancreatic beta cells in patients with newly-diagnosed type 1 diabetes mellitus.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal